An effective diagnosis method for single and multiple defects detection in gearbox based on nonlinear feature selection and kernel-based extreme learning machine

Gear transmissions have been widely used in most of today’s manufacturing and production industries; however, they often suffer from deteriorations and damages on gear pairs. Severe damages of the machinery caused by the failures of gears account for 48 %, leading to significant economic losses. Therefore it is crucial to implement fault diagnosis procedure for gearboxes. The gear meshing motion is a kind of typical strong nonlinear movement, and the related vibration signals are the nonlinear mixtures of different kinds of vibration source, leading to great difficulty in the fault feature extraction and fault detection. In order to improve the fault detection of gearboxes, a new method based on the nonlinear fault feature selection and intelligent fault identification is proposed in this work. The blind source separation (BSS) procedure was firstly employed to eliminate the influence of noise signal sources. The useful information related to the fault vibration was hence separated by the independent component analysis (ICA). Then the spectral regression (SR) was used as a nonlinear feature selection technique for the separated vibration sources. Hence, distinct fault features can be obtained. Lastly, the kernel-based extreme learning machine (KELM) was applied for the pattern recognition of single and multiply faults of the gearbox. The fault vibration data acquired from a gearbox fault experimental tester was used to valuate the proposed diagnostic method. The experiment results show that useful fault vibration signals can be separated by the new method, and the fault detection rate of the proposed method is superior to the existing approaches with an increase of 4.4 % or better. Hence, this new development will produce considerable savings by reducing unplanned outages of machinery so a company can get the full benefit from condition monitoring

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)